Post by selluwud on Aug 26, 2015 12:23:06 GMT
Licensing agreement provides Knight commercial rights in Canada to Advaxis's product portfolio including axalimogene filolisbac (ADXS-HPV), ADXS-PSA and ADXS-HER2 Advaxis is eligible to receive up to $30 million in milestone payments from Knight
finance.yahoo.com/news/advaxis-announces-licensing-agreement-knight-120000197.html
Cash balance increased by 25 million with direct stock purchases at 13.91/share.
finance.yahoo.com/news/advaxis-announces-licensing-agreement-knight-120000197.html
Cash balance increased by 25 million with direct stock purchases at 13.91/share.